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Genetic differences in cytochrome P450 (CYP)-mediated metabolism have been known
for several decades. The clinically most important polymorphic CYP enzyme is CYP2D6,
which plays a key role in the metabolism of many antidepressants and antipsychotics,
along with a range of non-psychiatric medications. Dose individualization based on
CYP2D6 genotype to improve the effect and safety of drug treatment has been an
ambition for a long time. Clinical use of CYP2D6 genotyping is steadily increasing;
however, for pre-emptive genotyping to be successful in predicting individual dose
requirements, high precision of genotype-to-phenotype translations are required.
Recently, guidelines for assigning CYP2D6 enzyme activity scores of CYP2D6 variant
alleles, and subsequent diplotype-to-phenotype translations, were published by the
Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch
Pharmacogenetics Working Group. Consensus on assigning activity scores of
CYP2D6 variant alleles and translating diplotype scores into CYP2D6 poor,
intermediate, normal, or ultrarapid metabolizer groups were obtained by consulting 37
international experts. While assigning enzyme activities of non-functional (score 0) and fully
functional (score 1) alleles are straightforward, reduced function variant alleles are more
complex. In this article, we present data showing that the assigned activity scores of
reduced function variant alleles in current guidelines are not of sufficient precision;
especially not for CYP2D6*41, where the guideline activity score is 0.5 compared to
0.05–0.15 in pharmacogenetic studies. Due to these discrepancies, CYP2D6 genotypes
with similar guidelinediplotype scores exhibit substantial differences in CYP2D6
metabolizer phenotypes. Thus, it is important that the guidelines are updated to be
valid in predicting individual dose requirements of psychiatric drugs and others
metabolized by CYP2D6.
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INTRODUCTION
The polymorphic enzyme CYP2D6 plays a key role in the
metabolism of around 25% of all clinically used drugs, among
which many are used in treatment of psychiatric diseases
(Ingelman-Sundberg, 2005; Milosavljevic et al., 2020; van
Schaik et al., 2020; van Westrhenen et al., 2020). CYP2D6
metabolizer phenotype is highly dependent on CYP2D6
genotype (Bradford, 2002; Ingelman-Sundberg, 2005; Gaedigk
et al., 2008; Caudle et al., 2020), which was recently shown to
significantly predict therapeutic failure of the antipsychotic
CYP2D6 drug substrate risperidone in a cohort of 1,288
patients (Jukić et al., 2019). This large-scale study shows that
there is a potential of personalized dosing of CYP2D6 drug
substrates based on CYP2D6 genotype, and hence improve
clinical outcome of many psychiatric drugs.
For the clinical utility, however, it is essential to provide
accurate CYP2D6 genotype-to-phenotype translations. Patients
are traditionally allocated to four different CYP2D6-metabolizer
phenotype subgroups: (1) poor metabolizer (PM), exhibiting
absent enzyme activity; (2) intermediate metabolizer (IM),
exhibiting reduced CYP2D6 enzyme activity; (3) normal
metabolizer (NM), exhibiting fully functional CYP2D6 enzyme
activity; and (4) ultra-rapid metabolizer (UM), exhibiting enzyme
increased CYP2D6 enzyme activity. Since more than
140 CYP2D6 variant alleles have been reported (www.
pharmvar.org/gene/CYP2D6; accessed December 2020),
encoding either no, reduced, fully functional or increased
CYP2D6 metabolism, genotype-to-phenotype translations into
the four metabolizer phenotype subgroups may be complicated.
More than 10-years ago a system for assigning enzyme
activity scores of the various CYP2D6 variant alleles was
established by Gaedigk and colleagues to standardize
genotype-to-phenotype translations (Gaedigk et al., 2018). In
this system, CYP2D6 variant alleles are assigned enzyme activity
scores between 0 and 1, referring to no (‘Null’) and fully
functional enzyme activities, respectively, and reduction-
function variants with a score of 0.5. Based on the assigned
activity score of the alleles, individual diplotypes scores are
calculated ranging from ‘0’ for Null/Null carriers to ‘≥3’ for
carriers of multiplications of fully functional alleles (Gaedigk
et al., 2008; Gaedigk, 2013; Hicks et al., 2017; Caudle et al.,
2020). The concept of the CYP2D6 ‘activity score’ has gained
acceptance as a simple tool for CYP2D6 genotype/phenotype
translations, and been adopted by the Clinical
Pharmacogenetics Implementation Consortium (CPIC), and
later by the Dutch Pharmacogenetics Working Group
(DPWG), with the intention to facilitate the application of
pharmacogenetics knowledge into clinical care.
While translating diplotype activity scores of CYP2D6 Null/
Null (AS  0) and CYP2D6*1/*1 (AS  2) into CYP2D6 PM and
NM phenotypes is straightforward, the diplotype score
translations into the heterogeneous IM subgroup are complex,
relying on the assigned activity scores of the reduced function
variant alleles, which to some extent have differed between CPIC
and DPWG. Thus, to standardize the CYP2D6 genotype/
phenotype translations, CPIC and DPWG recently published
consensus guidelines on the assignment of activity scores of
specific variant alleles for diplotype-based allocations into
CYP2D6-metabolizer groups. In the new guidelines, the most
relevant reduced function variants were assigned activity scores of
0.25 or 0.5.
The following diplotype score-to-phenotype translations are
defined by the consensus guidelines: i) score 0 to PM, ii) scores >0
and ≤1.25 to IM, iii) scores >1.25 and ≤2.25 to NM, and iv) scores
>2.25 to UM (Caudle et al., 2020). Furthermore, ‘PM spectrum’
was introduced as a new term referring to diplotype scores
between 0 and ≤0.25. Accordingly, the assigned activity scores
of reduced function variant alleles may determine the overall
diplotype score, and hence the metabolizer-phenotype group
allocation, phenotype ‘ranking’ within the heterogeneous IM
group, and ultimately the precision of the CYP2D6 genotype-
to-phenotype translation.
In the literature, the activity scores of the specific reduced
function variants are not consistently defined. Thus, CYP2D6
genotype/phenotype translations of reduced function diplotypes
allocated to the IM group by the guideline diplotypes may be
uncertain. Furthermore, other factors than the CYP2D6-
metabolizer phenotype determines drug clearance, which may
limit the usefulness of the diplotype activity score in predicting
individual exposure and dose requirements of CYP2D6 drug
substrates. This article provides perspectives on these issues
aiming to:
(1) critically assess the assigned activity scores of reduced
function CYP2D6 variants in current guidelines vs. human
in vivo pharmacogenetic studies in relation to defining
intermediate metabolizers.
(2) evaluate the CYP2D6 activity score model as a tool for
predicting exposure and personalized dose requirements of
drugs metabolized by CYP2D6.
(3) discuss future directions for CYP2D6 genotype-based
algorithms in predicting individual dose requirements of
CYP2D6 drug substrates.
SUBSECTIONS
Assigned Activity Scores of CYP2D6
Reduced Function Variant Alleles in Current
Guidelines
In the guidelines from CPIC and DPWG, consensus on activity
score assignments of specific CYP2D6 variant alleles and
genotype-to-phenotype translations were reached via
interviews/opinions of 37 experts by the Delphi survey
technique (Caudle et al., 2020). The most studied CYP2D6
reduced function variant are CYP2D6*9, CYP2D6*10 and
CYP2D6*41. The activity scores of CYP2D6*9 and CYP2D6*41
were defined as 0.5, while CYP2D6*10 was assigned an activity
score of 0.25.
Interestingly, 44% of the members of the consensus group
voted for defining diplotype scores ≤0.25 as pM. This was the
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basis for describing diplotypes scores between 0 and 0.25 to be in
the ‘PM spectrum’ on the proposed linear activity score
continuum. The latter is probably the major consequence of
differentiating the activity score of CYP2D6*10 from
CYP2D6*9 and CYP2D6*41. CYP2D6*10/Null carriers then are
allocated in the ‘PM spectrum’ (score ≤25%), while CYP2D6*9/
Null and CYP2D6*41/Null carriers are translated into the ‘pure’
IM group along with homozygous carriers of CYP2D6 reduced
function alleles and CYP2D6*1/Null carriers. Similarly,
CYP2D6*1/*10 carriers (AS 1.25) are allocated to the IM
group, while CYP2D6*1/*9 and CYP2D6*1/*41 carriers are
defined within the NM group. Thus, the assigned activity
scores of CYP2D6*10 vs. CYP2D6*9 and CYP2D6*41 is the
most critical point of the genotype-to-phenotype translation in
current guidelines, which should be compliant with reported
activity scores in human pharmacogenetic studies on CYP2D6
substrates.
Activity Scores of CYP2D6 Reduced
Function Variant Alleles in
Pharmacogenetic Studies
In the literature, there are several well-powered in vivo
pharmacokinetic/genetic studies with a range of different
CYP2D6 drug substrates where the CYP2D6 activity scores of
reduced function variants can be calculated. The activity score
(AS) of the respective reduced function variant (X) can be
calculated using the following formula based on metabolic
ratios (MR) of the CYP2D6 drug substrates in different
genotype subgroups (Haslemo et al., 2019):
AS of X  (MR X/Null −MRNull/Null)
: (MRWt/Null −MRNull/Null)
[Null alleles comprising CYP2D6*3, CYP2D6*4, CYP2D6*5 and
CYP2D6*6, while absence of detected variant alleles definingWild
type (Wt; CYP2D6*1)].
Using this formula, we calculated the CYP2D6 residual
enzyme activity scores of the most relevant reduction-function
variants (CYP2D6*9, CYP2D6*10 and CYP2D6*41) against the
metabolism of different CYP2D6 substrates (Table 1). In the
Table, some data on the reduced function allele CYP2D6*17,
which is frequent in Africans and Afro-Africans, are also
presented.
Together, the studies used to calculate the activity scores
comprise several thousands of patients (Table 1). Regardless
of the substrate, the encoded CYP2D6 metabolism is
unambiguously lower for CYP2D6*41 than for CYP2D6*9 and
CYP2D6*10. For the typical CYP2D6 substrates
dextromethorphan, risperidone, tamoxifen and venlafaxine, the
reported enzyme activity score of CYP2D6*41 is between 0.04 and
0.12 compared to 0.5 in the CPIC/DPWG consensus guidelines.
The activity scores of CYP2D6*9 and CYP2D6*10 are quite
similar between different substrates and both variant alleles
seem to encode an enzyme activity score of in the range
0.2–0.35, possibly with a somewhat lower relative activity of
CYP2D6*10 in East-Asian than in Europeans populations
(Table 1).
CYP2D6*17 is a common reduced function variant in African
and Afro-African populations but rarely found in other ethnic
groups. In a study by Wennerholm et al. (2002), the CYP2D6
TABLE 1 | The most relevant reduced function variants with the respective mutations and frequencies in different ethnic groups, and activity scores defined by the CPIC/
DPWG consensus guidelines vs. activity scores calculated from pharmacogenetic studies with various CYP2D6 substrates.
Variant Variant frequencies, % Activity scores CYP2D6 substrate Population Participants, n References
Europe Asia African CPIC/DPWG Reported
CYP2D6*9 2 <0.5 <0.5 0.5 0.34a Venlafaxine Norwegian 1,003 Haslemo et al. (2019)
0.18a Risperidone Norwegian 1,318 Jukić et al. (2019)
0.28a Aripiprazole Norwegian 1,437 Jukić et al. (2019)
0.22 Vortioxetine Mixed 1,140 Frederiksen et al. (2020)
CYP2D6*10 3 40 5 0.25 0.34a Venlafaxine Norwegian 1,003 Haslemo et al. (2019)
0.18a Risperidone Norwegian 1,318 Jukić et al. (2019)
0.28a Aripiprazole Norwegian 1,437 Jukić et al. (2019)
0.37 Vortioxetine Mixed 1,140 Frederiksen et al. (2020)
0.22 Dextromethorphan Japanese 162 Kubota et al. (2000)
0.10 Dextromethorphan Japanese 98 Tateishi et al. (1999)
CYP2D6*17 <0.5 <0.5 20 0.5 0.17 Vortioxetine Mixed 1,140 Frederiksen et al. (2020)
0.54 Metoprolol Tanzanian 35 Wennerholm et al. (2002)
0.09 Dextromethorphan Tanzanian 35 Wennerholm et al. (2002)
0.46 Codeine Tanzanian 35 Wennerholm et al. (2002)
0.12 Debrisoquine Tanzanian 35 Wennerholm et al. (2002)
CYP2D6*41 8 <0.5 3 0.5 0.09 Venlafaxine Norwegian 1,003 Haslemo et al. (2019)
0.04 Risperidone Norwegian 1,318 Jukić et al. (2019)
0.17 Aripiprazole Norwegian 1,437 Jukić et al. (2019)
0.21 Vortioxetine Mixed 1,140 Frederiksen et al. (2020)
0.12 Dextromethorphan German 36 Abduljalil et al. (2010)
0.10 Tamoxifen Swedish 118 Thorén et al. (2020)
aCYP2D6*9 and CYP2D6*10 merged.
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enzyme activity of CYP2D6*17 was investigated in Tanzanians
(n  35) healthy volunteers after administration of the CYP2D6
substrates codeine, debrisoquine, dextromethorphan and
metoprolol for at least seven days. A unique aspect of this
study was that the enzyme activities of multiple CYP2D6
substrates could be calculated in the same subgroups
(Wennerholm et al., 2002). A striking finding was that the
enzyme activity score CYP2D6*17 toward debrisoquine and
dextromethorphan metabolism was 0.10, while the activity
scores were around 0.50 for CYP2D6-mediated metabolism of
codeine and metoprolol. This shows that the impact of this
variant on CYP2D6 metabolism may be substantially affected
by the substrate, which complicates the CYP2D6 genotype-to-
phenotype translations.
The inconsistencies between the CYPD6 activity scores of the
reduced function variants CYP2D6*41 and CYP2D6*9 defined in
the current guidelines and those estimated from in vivo
pharmacokinetic/genetic studies have a great impact on the
calculated activity scores of the respective diplotypes, and
hence the CYP2D6 genotype-to-phenotype translations. This is
particularly relevant in the IM group, where many diplotypes
comprise reduced function variants. Thus, for the assigned
enzyme activity scores in the guidelines to be valid, the
CYP2D6 phenotypes translated from different genotypes with
the same diplotype scores should be similar.
CYP2D6 Metabolism in IM Patients with
Different Genotypes and Similar Guideline
Diplotype Scores
To evaluate the precision of the guideline-assigned CYP2D6
diplotype scores in predicting CYP2D6 metabolizer
phenotypes, we compared CYP2D6 metabolism in patients
with different CYP2D6 genotypes but similarly defined
diplotype activity scores consistent with an IM phenotype
according to the CPIC/DPWG guidelines. The diplotype-to-
phenotype consensus translations were evaluated using data
from previous studies on three psychiatric CYP2D6 drug
substrates, i.e., venlafaxine, aripiprazole and risperidone
(Haslemo et al., 2019; Jukić et al., 2019), where we had access
to raw data from individual patients.
As shown in Figure 1 there were extensive differences in
CYP2D6 metabolism toward venlafaxine, risperidone and
aripiprazole between IM patients with similar CYP2D6
diplotype scores, but different CYP2D6 genotypes. One of the
characteristic features was the consistently lower metabolism in
CYP2D6*41/*41 carriers (diplotype score 1) than for the other
IM-allocated genotypes with a diplotype guideline-score of 1
(Figure 1). Furthermore, the CYP2D6*41/*41 carriers (score 1)
exhibited similar or lower metabolic ratios than CYP2D6*10/Null
carriers (score 0.25) for all drugs (Figure 1). The CYP2D6*10/
Null carriers are by the consensus guidelines proposed to exhibit
CYP2D6-metabolizer phenotypes in the PM spectrum, but their
metabolic ratios were substantially higher than for CYP2D6*41/
Null carriers among patients treated with venlafaxine, risperidone
and aripiprazole.
From the evidence provided from the above comparisons in big
patient cohorts, it is clear that the assigned activity scores of the
reduced function variants in the CPIC/DWPG guidelines do not
comply with CYP2D6-metabolizer phenotypes observed among
IM patients with similar CYP2D6 diplotype activity scores
originating from different CYP2D6 genotypes. Thus, in clinical
practice, the use of the current consensus guideline for diplotype-
based CYP2D6 genotype-to-phenotype translations does not
predict individual CYP2D6-metabolizer phenotypes with
sufficient precision. Instead of using the CYP2D6 diplotype
activity score as a surrogate measure of CYP2D6-mediated
hepatic clearance, we propose applying the actual CYP2D6
genotype to predict dose requirements of specific CYP2D6 drug
substrates based on genotype-specific exposure in
pharmacogenetic/kinetic studies. However, when predicting
individual dose requirements of a specific CYP2D6 drug
substrate, it is essential to account for other variables than the
CYP2D6 genotype that may determine its systemic exposure.
FIGURE 1 | Metabolic ratios of O/N-desmethylvenlafaxine (A), 9-hydroxyrisperidone/risperidone (B) and dehydroaripiprazole/aripiprazole (C) according to
CYP2D6 genotypes with similar diplotype activity scores as defined by the CPIC/DPWG consensus guidelines (Caudle et al., 2020). The vertical dashed lines indicate the
spectra of different CYP2D6 genotypes that are allocated to the same diplotype activity scores. The metabolic ratios, presented as geometric means with 95%
confidence intervals, are based on data from publications by Haslemo et al., 2019 (A) and Jukić et al., 2019 (B,C). Diplotype scores >0 to ≤1.25 (shaded) are by the
consensus guidelines translated to CYP2D6 intermediate metabolizer (IM) group.
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Dose Predictions of CYP2D6 Drug
Substrates Beyond CYP2D6 Genotype
As various CYP2D6 drug substrates exhibit different
pharmacokinetic properties, it is necessary to account for
other factors than CYP2D6 genotype when predicting
individual clearance values (Mehvar, 2018), and subsequently
dose requirements of both psychiatric and other medications.
While the CYP2D6 genotype only predicts the partial intrinsic
CYP2D6-mediated hepatic clearance (CLint-2D6), i.e. Km and/or
Vmax values, the hepatic extraction ratio reflects the overall drug
clearance in relation to hepatic blood flow (organ drug delivery)
(Mehvar, 2018). For CYP2D6 drug substrates with a high
extraction ratio (E > 0.7), blood flow rather than CYP2D6
genotype (CLint-2D6) is the key variable determining individual
hepatic clearance. However, for low-extraction drugs (E < 0.3),
CYP2D6 genotype (CLint-2D6) and free fraction in plasma
determine hepatic clearance. Most drugs have a low or
medium hepatic extraction ratio, implying that CYP2D6
genotype (CLint-2D6) and free fraction in plasma are the main
factors to take into account when predicting individual dose
requirements of CYP2D6 drug substrates (Mehvar, 2018). In
addition, body weight, kidney function etc. may be other relevant
parameters physiological to take into account as integral parts of
dosing algorithm.
Patients often use multiple medications concurrently, which
imply that drug-drug interactions represent an issue that needs to
be consider when predicting appropriate dosing of CYP2D6 drug
substrates. For patients being genotype-predicted CYP2D6 NMs,
phenoconversion to pMs may occur during concomitant
treatment with potent CYP2D6 inhibitors, e.g. the
antidepressants bupropion, fluoxetine and paroxetine. A point
is also that CYP2D6 substrates may be subjected to considerable
metabolism via other enzymes, which is an aspect of importance
for the sensitivity toward altered CYP2D6 activity. Thus, for
genotype-based dose predictions of CYP2D6 drug substrates to
be of relevance at all, it is necessary that CYP2D6 plays a major
role in the overall metabolism/clearance of the drug. It is difficult
to define a ‘major role’, but one may consider that CYP2D6
metabolism should be mediating at least 50% of the overall
clearance for differences in CYP2D6 activity to be of general
relevance. However, the exact relevance will differ between
various CYP2D6 drug substrates.
DISCUSSION
We have in this article critically highlighted the assigned enzyme
activity scores of the CYP2D6 reduced function variants and the
corresponding genotype-to-phenotype translations of the
CYP2D6 IM group in the current CPIC/DPWG guidelines. A
major issue is that the guideline-defined CYP2D6 enzyme activity
score of the reduced function variant CYP2D6*41 is not
compliant with the literature. It is crucial to update the
consensus guidelines on this point, and it should be clarified
that patients carrying the CYP2D6*41/Null genotype exhibit a
CYP2D6-metabolizer phenotype close to the PM subgroup,
which is evident from studies on many CYP2D6 drug
substrates (Table 1; Figure 1).
The large inconsistencies in CYP2D6 metabolism between
various IM genotypes with similar diplotype scores show the
inadequacy of the consensus activity score model in predicting
individual hepatic clearance and dose requirements of CYP2D6
drug substrates. These inconsistencies may have important
clinical implications for genotype-based dose
recommendations of many psychiatric drugs, as CYP2D6
generally plays a key role in the metabolism of such agents.
However, the same concerns CYP2D6 drug substrates from other
therapeutic classes, e.g., tamoxifen, where Thorén et al. (2020)
reported a significantly stronger impact of CYP2D6*41 than
CYP2D6*10 on the CYP2D6-mediated bioactivation to
endoxifen (Thorén et al., 2020), which mainly mediates the
preventive effect on breast cancer recurrence.
While the consensus guidelines define CYP2D6*41 with an
activity score of 0.5, the published activity scores in
pharmacogenetic studies on multiple CYP2D6 substrates are
typically in the range 0.05–0.15 (Table 1). The CYP2D6*41
variant allele includes the 2988 G > A polymorphism, which
encodes a splicing defect reducing the CYP2D6 enzyme
expression by around 90% according to in vitro studies
(Raimundo et al., 2004; Toscano et al., 2006). Thus, by
reducing the hepatic CYP2D6 levels (Vmax) the relative effects
of on the CYP2D6-mediated Clint is expected to be approximately
the same regardless of substrate.
While previously defining all reduced function variant alleles
with an activity score of 0.5, the revised CPIC/DPWG consensus
guidelines recently down-adjusted the activity score assignment
of CYP2D6*10 to 0.25. Actually, an activity score of 0.25 for
CYP2D6*10 is in line with the literature (Table 1). For CYP2D6*9,
which has a low frequency across different ethnic groups,
available in vivo evidence (Table 1; Figure 1) suggests an
enzyme activity score of 0.25 as well. Patients carrying
CYP2D6*9/Null or CYP2D6*10/Null could therefore be merged
into a common diplotype-translated CYP2D6 IM phenotype
(Figure 1). The data presented here on the CYP2D6
metabolism shown in CYP2D6*41/*41 carriers suggest that
these patients can also be merged with CYP2D6*9/Null or
CYP2D6*10/Null carriers in an IM subgroup in the lower end
of the phenotype scale (Figure 1). According to the data shown
in the present article, the diplotype score of CYP2D6*41/Null will
be around 0.1, i.e. within the spectrum of the CYP2D6 PM
phenotype (Figure 1).
Today, new marketed CYP2D6 drug substrates have results
from pharmacogenetic studies that could be used for the
development of CYP2D6 genotype-based dosing algorithms in
clinical practice. It is therefore important that medicines agencies
and clinicians demand such data to be made available for the best
possible prescription, and not to allow the option that such data
may be kept unavailable by the manufacturer. There is an
apparent conflict of interest in this regards, since for the
manufacturer, for the marketing purposes, it is most
favourable to have a ‘one-size-fits-all’ drug, for which is not
necessary to adjust the dose individually, based on the procedures
including genotyping.
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The data presented here were from populations mainly
comprising Caucasians. The important point is that there might
be inter-ethnic differences in the impact of the same variant on the
metabolism of CYP2D6 drug substrates. An example is
CYP2D6*10, which may seem to have a greater effect on
CYP2D6 metabolism in East Asians than in Europeans
(Table 1). Thus, another aspect with regulatory demands, it that
pharmacogenetic studies should be performed across ethnic groups.
Finally, for CYP2D6 drug substrates with active metabolites, factors
determining the clearance of the active metabolites also need to be
accounted for when predicting dose requirements. An example
reflecting the relevance of this aspect is risperidone, where renal
function determines the subsequent clearance of the active
metabolite 9-hyrdoxyrisperidone (paliperidone). Consequently, a
risperidone-treated CYP2D6 IM patient with renal failure, where
both risperidone and paliperidone are accumulated, obtains a
substantially larger effect on the exposure of active moiety than
predicted from the CYP2D6 genotype itself.
In summary, we propose that genotype-to-phenotype
translations of the heterogeneous IM group should be revised
in the CPIC/DPWG guidelines; mainly due to the discrepancies
between the guideline-assigned activity scores of CYP2D6
reduced function alleles and those calculated from
pharmacogenetic studies with multiple CYP2D6 drug
substrates. In particular, it is critical to correct the guidelines
on the assigned activity score of CYP2D6*41. Carriers of
CYP2D6*41/Null diplotype obviously exhibit significantly lower
CYP2D6-metabolizer phenotypes than carriers of the CYP2D6*9/
Null or CYP2D6*10/Null diplotypes, and should rather be defined
within the PM spectrum.
Furthermore, we have highlighted that different CYP2D6
genotypes assigned the similar CYP2D6 diplotype activity
scores by the CPIC/DPWG consensus guidelines exhibit
substantial differences in CYP2D6 metabolism. In this
perspective, we propose leaving the simple CYP2D6 diplotype
activity score model and instead use the actual CYP2D6 genotype
as is - without any phenotype translations - in algorithms
predicting individual dose requirements. Provided known
effects of CYP2D6 genotypes on the exposure of specific
drugs, the measured CYP2D6 genotype, as a proxy of the
individual patient’s CLint-2D6, could be incorporated into
drug-specific dose algorithms, where other significant,
concentration-determining variables are integrated. Since
many psychiatric drugs are metabolized by CYP2D6,
development of such genotype-based dose algorithms may
meet the expectations of personalized treatment of patients
with psychiatric disorders.
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